Hospital
Catholic Medical Center
Catholic Medical Center was paid $19.82M by Medicaid between Jan 2018 and Dec 2024, across 265 billing codes. Its largest line is 99285, emergency room visit (most serious) — 17% of everything it billed.
33Billing provider infoCATHOLIC MEDICAL CENTER
MANCHESTER, NH 03102
MANCHESTER, NH 03102
33aNPI1528150273assigned 09/29/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$19.82M
24GClaims607,005
24DCodes billed265
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in New Hampshire
Rank by total paid#1 of 5
Median peer was paid$54K
This provider vs. median365×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 118,854 | $2.82M | |
| 2019 | 135,847 | $3.83M | |
| 2020 | 88,222 | $2.59M | |
| 2021 | 112,514 | $3.87M | |
| 2022 | 88,232 | $3.61M | |
| 2023 | 35,619 | $1.70M | |
| 2024incomplete | 27,717 | $1.40M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 15,810 | 12,499 | $3.40M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 17,254 | 14,356 | $3.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.1% | 13,170 | 11,375 | $1.40M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.4% | 3,426 | 2,809 | $1.26M |
| G0378 | Hospital observation service, per hour | 2.6% | 4,412 | 3,221 | $519K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.3% | 2,369 | 1,905 | $463K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.3% | 4,223 | 3,933 | $448K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 3,902 | 3,008 | $444K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 7,600 | 4,815 | $430K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 9,025 | 6,015 | $421K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 13,169 | 9,847 | $384K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 19,759 | 15,516 | $340K |
253 more codes
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 10,345 | $324K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.5% | 1,140 | $290K |
| 80053 | Comprehensive metabolic panel | 1.5% | 45,085 | $288K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 8,367 | $278K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 5,889 | $229K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 876 | $225K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 45,829 | $216K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 8,303 | $215K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 24,541 | $183K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 719 | $180K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,566 | $175K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,091 | $169K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,132 | $158K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 248 | $142K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,519 | $133K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,932 | $130K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,625 | $124K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 946 | $123K |
| 93017 | <1% | 1,149 | $121K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,274 | $108K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,354 | $99K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 737 | $95K |
| 84484 | <1% | 14,288 | $94K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,559 | $87K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 212 | $85K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,519 | $83K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,809 | $80K |
| 80061 | Lipid panel | <1% | 7,951 | $78K |
| 93351 | <1% | 163 | $78K | |
| 76801 | <1% | 816 | $76K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,931 | $74K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,734 | $73K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,441 | $71K |
| 96376 | <1% | 2,389 | $54K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,694 | $53K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,688 | $53K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 193 | $53K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 938 | $51K |
| 84703 | <1% | 9,478 | $49K | |
| 93320 | <1% | 608 | $49K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,061 | $49K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,061 | $48K |
| 93325 | <1% | 755 | $45K | |
| 83880 | <1% | 2,659 | $43K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 555 | $41K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,955 | $39K |
| 93971 | <1% | 644 | $39K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,612 | $36K |
| 97161 | <1% | 1,155 | $35K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 212 | $34K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,440 | $34K |
| 87631 | <1% | 356 | $32K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,500 | $32K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,854 | $31K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,219 | $29K |
| 86850 | <1% | 3,840 | $29K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 807 | $29K |
| 76830 | Ultrasound, transvaginal | <1% | 399 | $28K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,869 | $28K |
| 85027 | <1% | 6,313 | $26K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,198 | $25K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 611 | $25K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 206 | $25K |
| 80074 | <1% | 677 | $25K | |
| 82728 | <1% | 2,478 | $24K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 86 | $23K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,597 | $23K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,863 | $22K |
| 95811 | <1% | 44 | $22K | |
| 72100 | <1% | 528 | $22K | |
| 97803 | <1% | 1,092 | $21K | |
| 83690 | <1% | 5,004 | $21K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 85 | $21K |
| 87070 | <1% | 3,271 | $21K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 668 | $20K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 219 | $20K |
| 93246 | <1% | 322 | $20K | |
| 97162 | <1% | 755 | $18K | |
| 84702 | <1% | 1,492 | $17K | |
| 81001 | <1% | 8,558 | $16K | |
| 73630 | <1% | 576 | $16K | |
| 87522 | Neg quan hep c or qual rna | <1% | 507 | $16K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 189 | $16K |
| 97597 | <1% | 475 | $15K | |
| 82607 | <1% | 1,812 | $15K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 36 | $14K |
| 71271 | <1% | 56 | $14K | |
| 87040 | <1% | 1,673 | $14K | |
| 36591 | <1% | 1,839 | $14K | |
| 73030 | <1% | 497 | $13K | |
| 86780 | <1% | 1,297 | $13K | |
| 87186 | <1% | 2,244 | $13K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,242 | $13K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 291 | $12K |
| 87077 | <1% | 2,340 | $12K | |
| 83735 | <1% | 3,316 | $12K | |
| 94060 | <1% | 224 | $12K | |
| 99157 | <1% | 172 | $12K | |
| 84439 | <1% | 1,858 | $12K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 130 | $11K |
| 83550 | <1% | 1,777 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,948 | $10K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,853 | $10K |
| 85610 | <1% | 5,515 | $10K | |
| 71250 | <1% | 79 | $10K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 507 | $10K |
| 83540 | <1% | 2,055 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 37,188 | $9K |
| 99156 | <1% | 200 | $9K | |
| 73610 | <1% | 324 | $9K | |
| C1769 | Guide wire | <1% | 221 | $9K |
| 82746 | <1% | 880 | $9K | |
| 86803 | <1% | 906 | $9K | |
| 87340 | <1% | 1,181 | $9K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 270 | $9K |
| 81003 | <1% | 8,582 | $9K | |
| 85379 | <1% | 1,321 | $9K | |
| 83605 | <1% | 1,252 | $8K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 551 | $8K |
| 80076 | <1% | 1,290 | $8K | |
| 93296 | <1% | 1,518 | $8K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,129 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,022 | $7K |
| 94726 | <1% | 277 | $7K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,266 | $7K |
| 94729 | <1% | 252 | $7K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 264 | $7K |
| 97802 | <1% | 190 | $7K | |
| 87081 | <1% | 1,470 | $6K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 347 | $6K |
| 86140 | <1% | 1,850 | $6K | |
| 96415 | <1% | 242 | $6K | |
| 86900 | <1% | 3,244 | $6K | |
| 86901 | <1% | 3,357 | $6K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,401 | $5K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 653 | $5K |
| 73564 | <1% | 157 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,681 | $5K |
| 99152 | <1% | 111 | $5K | |
| 82043 | <1% | 1,195 | $5K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 305 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 730 | $5K |
| 80050 | General health panel | <1% | 604 | $4K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 271 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,234 | $4K |
| 85652 | <1% | 2,035 | $4K | |
| 87205 | <1% | 1,429 | $4K | |
| 86403 | <1% | 478 | $4K | |
| 88342 | <1% | 310 | $4K | |
| 86762 | <1% | 301 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 31 | $3K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 396 | $3K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 117 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 42 | $3K |
| 70498 | <1% | 12 | $3K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 45 | $3K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 748 | $3K |
| 86618 | <1% | 176 | $3K | |
| 87634 | <1% | 109 | $3K | |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 119 | $3K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,835 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,889 | $3K |
| 73130 | <1% | 109 | $3K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 41 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,246 | $3K |
| 93970 | <1% | 33 | $2K | |
| 76642 | <1% | 57 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 19 | $2K |
| 99201 | <1% | 141 | $2K | |
| 73502 | <1% | 97 | $2K | |
| 73562 | <1% | 99 | $2K | |
| 86481 | <1% | 52 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 47 | $2K |
| 86038 | <1% | 210 | $2K | |
| 85730 | <1% | 425 | $2K | |
| 97165 | <1% | 43 | $2K | |
| 93880 | <1% | 22 | $1K | |
| 83615 | <1% | 390 | $1K | |
| 90715 | <1% | 335 | $1K | |
| 0296T | <1% | 117 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 92 | $1K |
| 76775 | <1% | 20 | $1K | |
| 82550 | <1% | 314 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 440 | $1K |
| 82950 | <1% | 300 | $1K | |
| 87210 | <1% | 504 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 973 | $1K |
| 97014 | <1% | 55 | $1K | |
| L5695 | Addition to lower extremity, above knee, pelvic control, sleeve suspension, neoprene or equal, each | <1% | 116 | $1K |
| 76536 | <1% | 13 | $1K | |
| 87902 | <1% | 13 | $1K | |
| 82565 | <1% | 336 | $1K | |
| 88313 | <1% | 82 | $990.19 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,929 | $937.73 |
| 96367 | <1% | 38 | $858.76 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,262 | $776.32 |
| 83970 | <1% | 33 | $764.29 | |
| 87075 | <1% | 159 | $738.57 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 34 | $686.10 |
| 85018 | <1% | 537 | $680.41 | |
| 84100 | <1% | 251 | $664.06 | |
| 97116 | <1% | 28 | $660.94 | |
| A9270 | Non-covered item or service | <1% | 6,134 | $583.08 |
| 88312 | <1% | 50 | $581.48 | |
| G0008 | Administration of influenza virus vaccine | <1% | 559 | $547.70 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 170 | $515.53 |
| 88304 | <1% | 29 | $512.21 | |
| 86706 | <1% | 66 | $493.68 | |
| 83655 | <1% | 49 | $488.18 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 103 | $487.58 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 142 | $476.64 |
| 90686 | <1% | 339 | $472.76 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 326 | $466.32 |
| 80320 | <1% | 30 | $445.00 | |
| 74018 | <1% | 12 | $413.33 | |
| 82803 | <1% | 29 | $404.28 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 110 | $391.25 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 17 | $327.87 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 45 | $312.10 |
| 85014 | <1% | 272 | $311.46 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,051 | $282.54 |
| 36416 | <1% | 354 | $263.61 | |
| 82570 | <1% | 69 | $259.90 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 13 | $248.13 |
| 84460 | <1% | 80 | $243.30 | |
| 84450 | <1% | 79 | $233.31 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 35 | $218.81 |
| 90662 | <1% | 249 | $185.47 | |
| 84520 | <1% | 105 | $182.25 | |
| 82105 | <1% | 12 | $167.48 | |
| 94664 | <1% | 29 | $164.29 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 24 | $156.26 |
| 94761 | <1% | 74 | $152.73 | |
| 86704 | <1% | 13 | $150.06 | |
| 80179 | <1% | 26 | $148.29 | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 28 | $140.78 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 16 | $135.86 |
| 82947 | <1% | 34 | $131.51 | |
| 86431 | <1% | 24 | $108.84 | |
| 83721 | <1% | 27 | $103.84 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 21 | $90.31 |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 15 | $78.72 |
| 94760 | <1% | 29 | $75.41 | |
| 84132 | <1% | 38 | $73.46 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 25 | $55.96 |
| 76999 | <1% | 14 | $52.05 | |
| 84156 | <1% | 16 | $48.13 | |
| 82248 | <1% | 22 | $43.69 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 43 | $30.30 |
| 81015 | <1% | 20 | $19.68 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 26 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 62 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 105 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTHERRIEN, ANDRE (CONTROLLER)
| Provider | Location | Paid |
|---|---|---|
| Catholic Medical Center | Manchester, NH | $465K |
| Catholic Medical Center | Manchester, NH | $134K |
| Catholic Medical Center | Manchester, NH | $677.30 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.